Nephrology drugs
8 results
Filspari (sparsentan)
(sparsentan)Travere Therapeutics, Inc.
Usage: FILSPARI is indicated for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
Jesduvroq (daprodustat)
(daprodustat)GlaxoSmithKline LLC
Usage: JESDUVROQ is indicated for treating anemia due to chronic kidney disease in adults on dialysis for at least four months. It is not intended for improving quality of life, nor for use as a substitute for red blood cell transfusions or in non-dialysis patients with anemia.
Jynarque (tolvaptan)
(tolvaptan)Otsuka America Pharmaceutical, Inc.
Usage: JYNARQUE is indicated for adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) to help slow the decline of kidney function.
Korsuva (difelikefalin)
(difelikefalin)Vifor (International) Inc.
Usage: KORSUVA is indicated for treating moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. It is not recommended for patients on peritoneal dialysis due to lack of study in that population.
Oxlumo (lumasiran)
(lumasiran)Alnylam Pharmaceuticals, Inc.
Usage: OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to reduce urinary and plasma oxalate levels in both pediatric and adult patients.
Procysbi (cysteamine bitartrate)
(Cysteamine bitartrate)Horizon Therapeutics USA, Inc.
Usage: PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients aged 1 year and older.
Vafseo (vadadustat)
(Vadadustat)Akebia Therapeutics, Inc.
Usage: VAFSEO is indicated for treating anemia in adults with chronic kidney disease who have been on dialysis for at least three months. It is not approved for improving quality of life or for patients not on dialysis. It should not replace red blood cell transfusions for urgent anemia correction.
Voraxaze (glucarpidase)
(glucarpidase)BTG International Inc.
Usage: VORAXAZE is indicated for reducing toxic plasma methotrexate concentrations in adults and pediatric patients with delayed clearance due to impaired renal function. It is not recommended for patients with expected methotrexate clearance, as this may lead to inadequate therapeutic exposure.